EMA Authorised: Conbriza (bazedoxifene) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Conbriza (bazedoxifene) for postmenopausal osteoporosis. The marketing authorization holder is Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Conbriza (bazedoxifene)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis, Postmenopausal. MAH: Pfizer Europe MA EEIG. Decision date: 19/05/2025